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Abstract Stem cells provide fascinating prospects for
biomedical applications by combining the ability to renew
themselves and to differentiate into specialized cell types.
Since the first isolation of embryonic stem (ES) cells about
30 years ago, there has been a series of groundbreaking
discoveries that have the potential to revolutionize modern
life science. For a long time, embryos or germ cell-derived
cells were thought to be the only source of pluripotency—a
dogma that has been challenged during the last decade.
Several findings revealed that cell differentiation from
(stem) cells to mature cells is not in fact an irreversible
process. The molecular mechanism underlying cellular
reprogramming is poorly understood thus far. Identifying
how pluripotency maintenance takes place in ES cells can
help us to understand how pluripotency induction is regu-
lated. Here, we review recent advances in the field of stem
cell regulation focusing on key transcription factors and
their functional interplay with non-coding RNAs.
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Introduction
Since the first isolation of embryonic stem cells about 30
years ago, there has been a series of fundamental devel-
opments in stem cell biology that have the potential to
revolutionize modern biomedicine. Stem cells exhibit very
special cellular properties by combining the ability to
renew themselves and to differentiate into specialized cell
types. Adult or somatic stem cells reside in multiple organs
of the organism, such as bone marrow, skin and brain (for
review, see [1, 2]). They can mature into a restricted subset
(or even just a single type) of specialized cells—a cellular
property designated as multi- and unipotency, respectively
(see Table 1 for definitions). Whereas somatic stem cells
exhibit a restricted differentiation potential, Evans and
Kaufman succeeded in establishing a very particular stem
cell type from an embryonic source [3] that is able to
differentiate into any cell type of the organism (pluripo-
tency). These so-called embryonic stem (ES) cells originate
from the inner cell mass (ICM) of blastocysts. Totipotent
cells, in contrast, can contribute to both embryonic and
extraembryonic tissue formation (Fig. 1). For a long time,
embryos or germ cell-derived cells were thought to be the
only source of pluripotency—a dogma that has been
challenged during the last decade. About 10 years ago,
Wilmut et al. reported the first production of a normal adult
mammalian (the sheep, ‘Dolly’) by transplanting the nuclei
of ex vivo cultured mammary gland cells into enucleated
oocytes (somatic cell nuclear transfer, SCNT) [4]. This
finding revealed that cell differentiation from (stem) cells
to mature cells is not an irreversible process. Actually,
early studies in frogs provided the first experimental evi-
dence that dedifferentiation may occur in non-mammalians
(for review, see [5]). The SCNT experiments by Wilmut
et al. demonstrated that the enucleated oocyte contains
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factors that are able to drive cellular reprogramming.
Although, these oocyte-specific factors remain so far
unidentified, it was the merit of Takahashi and Yamanaka
to show that two particular genes, Oct4 and Sox2, which
are necessary to maintain pluripotency, are also part of the
machinery that is able to induce pluripotency in somatic
cells [6]. They demonstrated that overexpression of Oct4
and Sox2 together with two other transcription factors,
c-Myc and Klf4, is sufficient to reprogram fibroblast cells
into ES-like cells, that have been referred to as induced
pluripotent stem cells (iPS cells). Nowadays, with these
molecular players of pluripotency induction identified, the
analysis of the molecular mechanism underlying factor-
induced reprogramming has developed into a major
research aim. In particular, the functional contribution of
each individual factor is being extensively studied.
Recently, c-Myc was found to be dispensable, since Klf4,
Sox2 and Oct4 were sufficient to induce iPS formation
albeit with decreased efficiency [7, 8]. More recently,
Scho¨ler et al. were able to reduce the number of virally
transduced reprogramming factors to only one, namely
Oct4, by employing neural stem cells that endogenously
express Sox2, cMyc and Klf4 [9]. They reasoned that Oct4
is indeed the key factor of pluripotency due to its expres-
sion profile during embryonic development. In fact, out of
the list of four ‘Yamanaka factors’, Oct4 is the only one
that is exclusively expressed in ES cells as well as in pri-
mordial germ cells (PGCs). Intriguingly, it has been
reported that PGCs can give rise to pluripotent cells
(termed embryonic germ cells) when cultured in a simple
cocktail of three growth factors [10, 11], which thus could
consequently be designated as a ‘No-factor-iPS-protocol’.
Taken together, the stem cell factors Oct4 and Sox2 turn
out to be essential to drive cellular reprogramming [9, 12,
13]. However, as for SCNT, the molecular mechanism
underlying factor-induced reprogramming is poorly
understood. Identifying how pluripotency maintenance
takes place in ES cells can help us to understand how
artificial induction of pluripotency is regulated.
Here, we review recent advances in the field of stem cell
regulation. A core set of stem cell-specific transcription
factors bind cooperatively to promoter regions of several
hundred genes involved in the regulation of pluripotency
and differentiation. We will summarize the activity of the
main factors and discuss their roles in the stem cell
machinery. While transcriptional regulation will be one
main emphasis of this review, the other focus will be the
recently disclosed interconnection between stemness
properties and non-coding RNAs. During the last few
years, these have become a key focus of scientific attention
as a new paradigm of gene expression regulation. Small
non-coding RNA molecules are able to influence expres-
sion at post-transcriptional level thereby adding another
level of complexity to transcriptional networks underlying
cellular diversity. We will discuss recent studies deci-
phering the role of non-coding RNAs in embryonic stem
cell biology and their functional interplay with the tran-
scriptional stemness machinery.
Transcriptional control over the stem cell machinery
During recent years, genetic loss- and gain-of-function
experiments as well as genome-wide binding analysis
revealed the importance of a limited set of transcription
factors for the maintenance of stem cell identity. Three
transcription factors, Oct4, Sox2 and Nanog (Table 2),
turned out to be particularly important, presumably
Table 1 Definitions of stem
cells’ differentiation capacities
Potency Example Developmental potential
Totipotent Fertilized oocyte Can give rise to both embryonic and extraembryonic tissues
Pluripotent ES cell Can give rise to every cell type of the body
Multipotent Hematopoeitic stem cell Can give rise to a certain limited number of cell types
Unipotent Spermatogonial stem cel Can give rise to a single cell type only
Fig. 1 Expression levels of key regulatory factors in ES cells impact
on their developmental potential. ES cells are derived from the inner
cell mass (ICM) of the blastocyst and exhibit a pluripotent differen-
tiation potential, i.e., they are able to differentiate into any cell type of
the body. The transcriptional network of pluripotency is mainly
regulated by three factors, Oct4, Sox2 and Nanog. If their expression
levels are altered in vitro (overexpression indicated by blue arrows,
loss-of function indicated by red arrows) ES cells differentiate toward
indicated lineages
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building the top of a transcriptional hierarchy of stemness.
Genome-wide DNA-binding analyses have shown that
these factors bind cooperatively to promoter regions of
several hundred genes involved in regulation of pluripo-
tency and differentiation [14–16]. Thus, understanding the
function of these putative master regulators will be
instrumental to decipher the stem cell machinery.
Structure and expression pattern of transcription factor
Oct4
Oct4 (also known as Oct3 and encoded by the Pou5f1
gene) is a member of the POU-Transcription factor family
(Pit, Oct, Unc) [17–19] that contains a bipartite DNA-
binding domain designated as POU-domain. It is divided
into a POU-specific (POUs) and a POU-homeo domain
(POUH), which are connected by a flexible loop. Oct-pro-
teins form a subfamily that bind to an octamer consensus
sequence [20]. Members of the Oct-protein-family (Oct1,
Oct2, Oct4 and Oct6) show high sequence homologies,
especially within regions involved in DNA-binding and
POU–POU interaction and are able to form different homo-
and heterodimers [21]. They vary in sequences of N- and
C-terminal domains that might be responsible for the
interaction with different groups of transcription factors
and coactivators [22]. In fact, the particular combination of
two DNA-binding domains not only confers the specificity
of the DNA binding but also provides the flexibility to
simultaneously interact with other proteins including reg-
ulatory factors.
During early embryonic development, Oct4 is present in
toti- and pluripotent cells [18, 19, 23–25]. At the blastocyst
stage, Oct4 is expressed in cells of the inner cell mass, but
repressed in trophectodermal cells by Cdx2 (Fig. 1) [26].
ES cells, which are derived from the ICM of a blastocyst,
seem to maintain this transcriptional fingerprint in vitro.
Upon differentiation Oct4 expression in ES cells is
downregulated induced by LIF withdrawal or treatment
with chemical inducers of differentiation such as retinoic
acid. After implantation of the blastocyst, Oct4 expression
is restricted to the epiblast and downregulated during
gastrulation. Later on, during embryonic development,
Oct4 expression is restricted to primordial germ cells [27].
Moreover, Oct4 is expressed in embryonic carcinoma and
germ cell lines [17, 24]. The clearly defined expression
pattern of Oct4, which is in vivo and in vitro restricted to
toti- and pluripotent cells, is indicative of the important
role of Oct4 in the maintenance of this developmental
particular status. Recently, it has been shown that the Oct4-
regulated gene set at the 1- and 2-cell stages of the early
embryo is to some extent different from the established
network in ES cells [28]. Antisense morpholino oligo-
nucleotide-mediated knock down of Oct4 in 1- to 2-cell
embryos showed that in the maternal-embryonic transition
Oct4 plays a dual function in post-transcriptional and
transcriptional regulation. By this, Oct4 is proposed to
affect either directly or indirectly many essential processes
during early development, such as chromatin regulation,
apoptosis, cell cycle regulation, and signaling [28].
Oct4 as a central player of pluripotency
Several genetic studies corroborate the role of Oct4 as a
master regulator of stemness. Oct4 knock-out embryos
develop until the blastocyst stage but they do not form a
normal ICM [23]. Consequently, ES cells cannot be
derived from Oct4-deficient blastocysts. In primordial
germ cells, the conditional deletion of Oct4 causes apop-
tosis [29]. Furthermore, RNAi-mediated knock down of
Oct4 in ES cells results in trophectodermal differentiation
of the cells (Fig. 1) [30, 31]. Our studies show that a cell-
permeable version of Oct4 could rescue the down-regula-
tion of Pou5f1 expression to a large extent [32]. Niwa et al.
showed by conditional overexpression of Oct4 that a pre-
cise expression level of Oct4 is necessary to sustain
pluripotency in ES cells, since about 50% reduced




Oct4 Octamer binding transcription factor 4 POU (Pit, Oct, Unc) domain transcription factor
Sox2 SRY (sex determining region Y)-related HMG box 2
transcription factor
HMG (High Mobility Group) of DNA-binding
proteins
Nanog Named after ‘Tir na nOg’ (Celtic mythology = land
of the ever young)
Homeodomain transcription factor
Cdx2 Caudal type homeobox transcription factor 2 Homeodomain transcription factor
Gata6 Binding of (G/A)GATA(A/T) DNA consensus GATA family of transcription factors
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expression already leads to trophectodermal differentiation,
whereas a two-fold elevated Oct4 level causes differenti-
ation to primitive endoderm and mesoderm [33] (Fig. 1).
Some studies aimed at assigning Oct4 a potential
function in non-embryonic and non-primordial germ cells.
It has been reported that Oct4 expression is essential for
induction of neural differentiation in ES cells by stromal
cell-derived inducing activity (SDIA). Moreover, sustained
upregulated Oct4 expression enhanced SDIA-mediated
neurogenesis [34]. However, by employing a genetic
approach to determine whether Oct4 is important for
maintaining multipotency in adult stem cells of several
somatic tissues including the intestinal epithelium, bone
marrow (hematopoietic and mesenchymal lineages), hair
follicle, brain, and liver, it was shown that Pou5f1 ablation
revealed no abnormalities in homeostasis or regenerative
capacity in these tissues [35]. Some studies assign Oct4 a
role in initiating tumorous growth, thereby determining the
dark side of stem cells. A report employing a mouse model
enabling inducible Oct4-expression in all tissues except
brain and testes showed that hyperplasia and invasive
tumor formation was induced cell-autonomously in epi-
thelial tissues, suggesting that precursor cells, present in
these tissues, are expanded and their differentiation is
inhibited [36]. In fact, it has been shown that an aberrant
activity of Oct4 may contribute to aneoplastic processes in
germ cells [37, 38].
How can a single factor accomplish such a variety of
functions? The way in which Oct4 acts on its target genes
shows remarkable diversity (Fig. 2a). The N- and C-ter-
mini of Oct4 act as transactivators and appear to function
redundantly to maintain self renewal [39]. In particular, it
could be shown that Oct4 molecules lacking either the
N- or C-terminal domain can efficiently replace full-length
protein. Even a heterologus transactivation domain of Oct2
fused with the POU domain can sustain self-renewal. This
implies that the Oct4 POU domain combined with a pro-
line-rich transactivation domain is sufficient to confer the
unique function of Oct4 in ES cells. While Oct4 has pre-
dominantly an activating effect on pluripotency related
genes like Sox2, Nanog and Pou5f1 itself [40–43], it is
indirectly involved in the inhibition of differentiation
processes. This is accomplished by activating so-called
‘‘repressors of differentiation’’ like Polycomb group pro-
teins (PcG), zink finger transcription factors, chromatin
remodeling factors, and suppressors of signaling [16]
(Fig. 3). Post-transcriptional modifications of Oct4 may
also result in differential activation potential as has been
recently reported. It was found that Oct4 phosphorylation
regulate formation of specific Oct4 homodimers with dif-
ferent subsets of target genes [44]. The functional
significance of this finding in vivo as well as in ES cells
remains to be investigated.
The role of Sox2 and its interplay with Oct4
Sox2 is a member of the High Mobility Group (HMG) DNA-
binding proteins. HMG proteins are unique in their DNA-
binding, since they induce a strong DNA bent through
binding to the minor groove of the DNA-helix. By this, HMG
proteins endow the chromosome with nuclease sensitivity
alluding to an essential role in maintenance and modulation
of chromatin structure. Moreover, HMG proteins recruit
transcription factors to bind to enhancers [45, 46]. The
HMG-domains of Sox (sry-related HMG-box) proteins show
highly similar DNA-binding properties, recognizing only a
6- to 7-base pair DNA-sequence. Additionally, Sox proteins
contain an activation-/repression-domain that is located at
Fig. 2 Transcriptional activities and protein–protein interactions of
stemness factors (modified from [158]). a Oct4 transcription factor
can directly activate gene transcription by binding to octamer sites
(first line). Activation may also occur via bridge proteins (second
line). Moreover, Oct4 can repress transcription by either direct
binding to promoters (third line) or neutralization of activators such
as FoxD3 (fourth line). b POU and HMG transcription factors such as
Oct4 and Sox2 confer their transcriptional activity often in concert on
target genes. Two examples are drawn schematically demonstrating
that Oct4 and Sox2 are able to form dissimilar structures of
heterodimers that act differently on particular downstream genes.
c Nanog is able to block differentiation signals induced by bone
morphogenic protein and intracellularly mediated by Smad1 through
heterodimerization with Smad1
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the C-terminus and an interaction domain through which
they interact with other partners. Sox proteins are grouped
depending on the homologies between their HMG domains;
this reaches over 90% within an individual group and about
60% between different groups [46, 47]. Sequence similari-
ties outside the HMG domain determine the sub-grouping of
Sox proteins. Sox2, together with Sox1 and Sox3, belongs to
the SoxB1 sub-group family [48]. Since the stability of the
Sox-DNA-complex is rather low compared to other potent
transcription activators (dissociation constant Kd= 10-9-
10-8 M), the interaction with coactivators might be instru-
mental in achieving a stable DNA-binding that results in
successful activation of the enhancer, which would explain
the cell type-specific action of Sox proteins [49]. For
instance, within early embryonic development Sox2 acti-
vates target genes by interacting with Oct4. During later
developmental stages, with Oct4 not being expressed any-
more, Sox2 interacts with Pax6 a major regulator of eye
development. The Sox2-Pax6 complex plays an important
role in lens development [50].
Sox2 expression is detected in the ICM of mouse blas-
tocysts and further sustains in epiblast [51]. Unlike Oct4,
Sox2 also plays a role during later stages of embryonic
development and in adult stem cells. After the start of
neurogenesis Sox2 is exclusively expressed in the neural
plate throughout embryogenesis [51–54], while in the adult
organism Sox2 is expressed in neural stem cells of the
ventricular zone in the emerging neural tube and their
progeny [54–56]. The important role of Sox2 during
embryonic development is indicated by the lethality of
Sox2-deletion mutants. Murine embryos with homo-
zygously deleted Sox2 do not develop an epiblast, and ES
cells lose the ability of proliferation and self-renewal and
differentiate into trophectoderm (Fig. 1) [51]. This
observation has been recently confirmed by RNAi-medi-
ated knock down and conditional knock out of Sox2 in ES
cells [57–60]. The two-fold overexpression of Sox2 has
been reported to result in the inhibition of expression of
different Sox2 target genes, causing the differentiation of
ES cells to neuroectoderm, mesoderm and trophectoderm,
but no endoderm [61] (Fig. 1). Thus, similarly to Oct4, a
well-balanced precise expression level of Sox2 seems to be
important for the maintenance of pluripotency.
POU-proteins are common interaction partners of Sox-
factors; together they regulate fundamental processes
during development [62]. For instance, a complex
between Drosophila Sox2 homolog protein fish hook/
Dichaete and the POU-protein Drifter/ventral vienless
(Dfr) plays a role in the development of the midline glia
[63, 64]. The heterodimerization between Oct4 and Sox2
provides in fact the best characterized example of a POU
and SOX partnership (Fig. 2b). Several functional studies
have shown that Oct4 and Sox2 directly interact when
binding to promoter regions to activate the expression of
pluripotency related genes including their own [40, 41,
65], as well as the expression of Nanog, Fgf4, Utf1, and
Fbx15 [42, 43, 66–68]. Together with Klf4, they activate
the expression of Lefty1 [69]. Interestingly, depending on
the target gene, Oct4 and Sox2 exhibit different levels of
cooperation [70]. These levels appear to result in gradu-
ally different transcriptional activity for downstream
genes like Fgf4 and Utf1, depending on the amount of
Oct4 and Sox2 proteins present in the cell. Due to a
higher level of cooperativity, Oct4 may require less Sox2
to heterodimerize and augment Utf1 activity than is the
case for Fgf4 (Fig. 2b). While the function of Oct4 in ES
cells has been extensively characterized, the role of Sox2
remained rather undetermined until recently. It has been
speculated that Sox2 acts synergistically with Oct4 to
activate Oct-Sox enhancers thereby regulating the
expression of pluripotency genes including Nanog, Utf1
as well as Oct4 and Sox2 itself (Fig. 2). However, there
has been no direct evidence that Sox2 is indeed required
for Oct-Sox enhancer activity in ES cells. Masui et al.
assessed the role of Sox2 employing an inducible Sox2-
null ES cell model. As expected, Sox2-deficient ES cells
rapidly differentiate mainly into trophectodermal lineage
thereby confirming Sox2 to be indispensable for main-
taining ES-cell pluripotency. However, unexpectedly Oct-
Sox enhancers remain active even in the absence of Sox2
protein. Moreover, forced expression of Oct4 is able to
rescue the pluripotency phenotype of Sox2-null ES cells.
These seemingly contradictory observations may be
explained by the fact that other Sox proteins present in ES
cells, like Sox4, Sox11 and Sox15, could replace the
function of Sox2 in coactivation to Oct4-Sox2-regulated
gene expression [60].
Fig. 3 Oct4/Sox2/Nanog form a core transcriptional network regu-
lating the stem cell machinery. Several hundred target genes are co-
occupied by Oct4, Sox2 and Nanog. They can be classified into two
groups of downstream genes exerting opposing functions. One group
includes genes associated with proliferation, chromatin modification
and signaling. On the other hand, the core network activates pathways
that lead to the inhibition of differentiation. Polycomb group (PcG)
proteins act as transcriptional repressors (for details see text)
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Expression of Nanog and its cellular activities
The identification of a third key player of pluripotency was
based on the functional analysis of the interplay between
extrinsic and intrinsic stemness signals of ES cells. The
cytokine leukemia inhibitory factor (LIF) is usually indis-
pensable for the cultivation of mouse ES cells [71], and
several genetic studies have shown that this extrinsic signal
of self-renewal is mediated intracellularly by Stat3 [72].
Neither Oct4 nor Sox2 gain-of-function is able to alter ES
cells’ dependence on LIF whereas Nanog overexpression is
able to overcome LIF-dependence of mouse ES cells [73,
74]. Nanog expression can be detected in the ICM of
murine blastocysts and the epiblast as well as in vitro in ES
cells. Upon differentiation, Nanog is generally downregu-
lated; however, it is still expressed in germ cells as well as
in tumorous cell lines [73, 75]. Interestingly, in contrast to
Oct4 and Sox2, Nanog is not homogeneously distributed
between ES cells. Its expression reflects a mosaic-like
pattern where Nanog-high populations as well as Nanog-
low but Gata6-positive populations can be found within the
culture dish. This properly reflects the situation observed in
the ICM of the blastocyst at E3.5, where the expression of
Nanog and Gata6 resembles a salt-and-pepper pattern [76].
Like Oct4, the Nanog protein contains a homeodomain,
exhibiting a structure which it shares with members of the
Nk-2 gene family concerning the position of the homeo-
domain although more than half of the amino acids differ
[74]. While there is homology between its orthologs within
different species, the Nanog homeoprotein seems to be
unique [77]. The most prominent representatives of
homeodomain transcription factors can be found within the
group of Hox genes, which were discovered in Drosophila
melanogaster about 30 years ago [78]. Through their
homeodomain, these transcription factors are able to bind
and interact with DNA. Hox proteins fulfil the complex
tasks like pattern formation [79] and segmentation during
morphogenesis [80] through their ability to target a broad
range of diverse binding sites. This is accomplished by
building heterodimeric complexes with co-factors like
Pbx1 and Meis1 and thereby occupying enhancer regions
of different sets of target genes (reviewed in [81]). This
strategy of binding variety through multimeric diversity is
similar to that observed in the cases of Oct4 and Sox2
(Fig. 2).
Transcriptional activities of Nanog and its interaction
with other proteins
Mouse Nanog is a three-domain protein consisting of 305
amino acids (aa) encompassing the N-terminal domain (aa
1–aa 95), the homeodomain which is located between aa 96
and aa 155, and the C-terminal part of the protein (aa 156–
aa 305) [73, 74]. Thus far, there is only few data on the
transcriptional activity of Nanog. Based on luciferase
reporter assays in HEK293, NIH3T3, and P19 as well as
mouse ES cells, both the N-terminal and the C-terminal
domain exhibit transcriptional activity, the C-terminal
domain being about 7 times more active [82]. Moreover,
this C-terminal domain itself comprises two parts exhibit-
ing strong activation capability. These transactivation
domains were designated as CD1 (aa 150–aa 197) and CD2
(aa 248–aa 305). A repetitive sequence in which every fifth
residue is a tryptophan, the so-called tryptophan repeat
(WR), was identified between aa 198 and aa 247 thus
located inbetween CD1 and CD2 [83]. Recent work shed
light on potential co-activators or Nanog-protein inter-
actors. Wang et al. identified various binding partners of
Nanog, such as Oct4, Nac1, Rif1, Dax1, and Zfp281, by co-
immunoprecipitation [84]. First evidence of a putative
homodimerization of Nanog was provided by work pub-
lished by Torres and Watt. Nanog shares homology with
Nkx2.5, which is known to form homodimers, and indeed
the authors observed Nanog–Nanog interaction by GST
pull-down experiments. Furthermore, they reported that
Nanog is able to bind NFkB thereby inhibiting pro-differ-
entiation activities and, in cooperation with Stat3,
maintaining pluripotency [85]. More recently, Mullin et al.
identified the exact position of the dimerization site within
the Nanog protein by reporting that Nanog self-associates
within the WR [86]. A further study confirmed the concept
of a Nanog dimerization through its WR [87]. The authors
performed size chromatography of ES cell nuclear extracts
revealing putative Nanog dimers. Using different truncated
Nanog mutants for co-immunoprecipitation, the position of
the dimerization domain was allocated to the WR, corre-
lating well with the data published by Mullin et al.
Interestingly, a mutant version of Nanog, incapable of self-
dimerizing, did not exhibit cytokine-independent self-
renewal in mouse ES cells as judged by colony formation
assays. In addition, the authors reported that forced
expression of a functional artificial Nanog dimer is able to
keep ES cells self-renewing independent of LIF whereas
overexpression of the dimerizing-deficient Nanog mutant
did result in a loss of typical ES morphology and differ-
entiation. In the presence of LIF, the Nanog dimer as well
as the monomeric variant increased the percentage of
uniformly growing undifferentiated colonies indicating
enhanced self-renewal. Furthermore, the authors showed
that dimerization is required for Nanog to be able to
interact with other pluripotency network proteins such as
Zfp281, Sall4, Dax1, and Zfp198 through co-immunopre-
cipitation experiments [87]. Besides homo-dimerization
Nanog has been reported to physically interact with Smad1
thereby blocking BMP-induced mesoderm differentiation
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of ES cells [88] (Fig. 2c). It also acts as a direct activator of
transcription for the Rex-1 promoter in concert with Sox2
[89]. Moreover, Sall4 was purified in a protein complex
together with Nanog and within this complex Nanog pos-
itively regulates its own expression as well as that of Sall4
[90]. Pereira et al. reported that Tcf3 is necessary to limit
steady-state levels of Nanog mRNA, protein and promoter
activity within pluripotent ES cells [91]. In addition, Nanog
is able to recruit a repression complex called NODE
(Nanog and Oct4 associated deacetylase). In this way,
Nanog interacts with Oct4 and the chromatin remodeling
machinery since the NODE complex possesses histone
deacetylase (HDAC) activity [92].
Genetic analysis of Nanog activity
As outlined above, forced expression of Nanog enables
mouse ES cells to self renew in the absence of LIF.
Differentiation in response to retinoic acid and
3-methoxybenzamide, two known reagents to promote
differentiation, is reduced in Nanog-overexpressing cells.
Embryoid body formation was reported to be hampered as
well. After Cre-mediated excision of a floxed Nanog
transgene the full differentiation potential of these cells
was verified by blastocyst injection that resulted in the
generation of healthy chimeric mice [73]. There is only few
data indicating that the function of Nanog might be con-
served between human and mouse ES cells since LIF has
been shown anyway not to play a role in the self-renewal of
human ES cells [93]. However, it has been reported that
enhanced expression of NANOG in human embryonic stem
cells enables them to feeder-free growth in unconditioned
media [94], indicating that Nanog in both mouse and
human ES cells integrates the essential extrinsic stemness
signals.
The activity of ectopically overexpressed Nanog in non-
ES cells has so far been poorly investigated. Several studies
employing cell fusion and iPS cells as model systems
assign Nanog a role in the induction of pluripotency in
mature cells. Increased levels of Nanog are able to promote
pluripotency transfer to the somatic cell genome as shown
in cell fusion experiments [95]. Nanog also appears to play
a role in the reprogramming process of human somatic
cells [96–98]. However, whereas Oct4 and Sox2 have been
shown to be essential for cell reprogramming, Nanog is
dispensable and seems to have only a promoting effect. A
possible role of Nanog during the reprogramming process
might be disclosed by experiments of ectopic Nanog
expression in somatic cells as well as in stem cells. It has
been published that expression of Nanog in NIH 3T3 cells
results in enhanced proliferation by promoting cells to
enter into S phase [99]. An observation reported by Zhang
et al. further supports a potential role of the Nanog protein
influencing the cell cycle, as the authors show that NA-
NOG is able to regulate S-phase entry in human embryonic
stem cells via transcriptional regulation of CDK6 and
CDC25A, two major cell cycle regulatory components
[100]. This observation correlates well with that of Mitsui
et al. in which they state that ablation of Nanog results in
decelerated cell growth in mouse ES cells [74]. Piestun
et al. also reported an increased growth rate of Nanog-
expressing NIH 3T3 cells. Moreover, this study reported a
transformed phenotype of the cells resulting from Nanog
expression as judged by cell foci formation [101].
Further insight into the role of Nanog was revealed by
loss-of-function studies. Ablation of Nanog results in loss
of pluripotency accompanied by an induction of extraem-
bryonic endoderm-associated expression of Gata6 [74] as
well as an up-regulation of trophectodermal marker genes
like CDX2 (Fig. 1) [102]. Besides endoderm and troph-
ectoderm differentiation, Ivanova et al. showed that Nanog
down-regulation by RNAi also induces the expression of
markers for epiblast-derived lineages, namely mesoderm,
ectoderm and neural crest cells [58].
Although Nanog and Oct4 as well as Sox2 share a high
percentage of their target genes, Nanog appears to fulfil a
particular and distinct function in the stem cell machinery.
In contrast to Oct4, Nanog expression exhibits a fluctuative
pattern in morulae during development [103]. Consistently,
Nanog was also reported to be heterogeneously expressed
in ES cells. Nanog-high populations express further
markers of pluripotency such as Oct4, whereas Nanog-low
cells also stained positively for primitive endoderm [76].
The heterogenous expression pattern of Nanog in ES cells
may indicate different subsets of a pluripotency state.
Genetic ablation of Nanog in ES cells provided a clue to
the distinct role of Nanog in the stem cell machinery.
Chambers et al. genetically deleted Nanog in ES cells by
Cre-mediated recombination and reported that Nanog-null
ES cells, although prone to differentiation, are still able to
self renew. In addition, after aggregation of Nanog-defi-
cient cells with wild-type morulae, they showed that
Nanog-/- cells can give rise to post-natal chimeras.
Moreover, to investigate whether Nanog-deficient cells can
contribute to further development, the authors assessed the
persistence of Nanog-null cells during development. They
showed that Nanog-/- cells are indeed present in the
soma of the genital ridge until E11.5. Consequently, Nanog
seems to be required for primordial germ cells to prosecute
the germ-cell development program beyond E11.5 [104].In
conclusion, these data indicate that, in contrast to Oct4 and
Sox2, Nanog is expendable for the maintenance of pluri-
potency but primarily acts in the establishment and
construction of the ICM and germ cell formation. While
Oct4 and Sox2 are necessary to direct the stemness
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program, Nanog appears to be dispensable for the house-
keeping machinery of pluripotency.
Genome-wide analysis of stemness factors target genes
Using genome-scale location analysis, sets of target genes
for OCT4, SOX2 and NANOG could be identified in the
human genome. A substantial amount of target genes was
revealed to be co-occupied by these three transcription
factors (Fig. 3). The regulatory circuitry seems to consist
of autoregulatory and feedforward loops in which first of
all the three transcription factors regulate the expression of
themselves. Additionally, events associated with the
maintenance of stemness-like proliferation, activation of
transcription factors and chromatin modifiers as well as
stem cell signaling get initiated. Beyond that, factors
involved in differentiation processes become downregu-
lated thereby inhibiting embryonic stem cells to acquire an
ectodermal, mesodermal or endodermal fate [14] (Fig. 3).
In mouse ES cells, Oct4 and Nanog also share a high
percentage of their target genes, just like in their human
counterparts. Nanog and Oct4 seem to control a cascade of
pathways governing pluripotency like REST, self-renewal
as seen with nMyc, genome surveillance like in the case of
Trp53, as well as cell fate determination [15]. Moreover,
Boyer et al. identified the polycomb group (PcG) proteins
as transcriptional repressors in mouse ES cells. The PcG
repressive complexes PRC1 and PRC2 co-occupy over 500
genes most of which are important developmental regula-
tors [105]. Besides these three seminal publications, further
investigation of the core regulatory network in pluripotent
cells turns out to be of immense interest [106–110].
Non-coding RNAs and pluripotency maintenance
During the last few years, a new paradigm of genetic
regulation has become a key focus of scientific attention.
Small non-coding RNA molecules are able to influence
expression at post-transcriptional level thereby adding
another level of complexity to transcriptional networks
underlying cellular diversity [111, 112]. In fact, recent
studies revealed exciting novel insights into the role of
non-coding RNAs in embryonic stem cell biology. In
general, there are several classes of RNAs that do not code
for a protein product. Most commonly known are those
involved in splicing (ribozymes) and translation (tRNAs).
More recently, new classes of non-coding RNAs were
identified, changing the classical view of RNAs being just
mediators of genetic information. Nowadays, RNA mole-
cules have been assigned an important role in the
regulation of biological systems representing highly
dynamic nucleotide regulators. Such newly identified non-
coding RNAs (ncRNAs) include microRNAs (miRNAs),
piRNAs and (endogenous) siRNAs all of which are defined
by their way of biogenesis. Endo-siRNAs and piRNAs
have been shown to be most abundant in germ cells and are
involved among others in anti-viral defense and regulation
of ‘‘selfish’’ DNA elements, such as repetitive elements and
retrotransposons [113–115]. It is likely that they also play
additional roles in the maintenance of stem cell charac-
teristics. However, since so far there are few data on endo-
siRNAs and piRNAs in ES cells, we will focus on the
rapidly evolving field of miRNAs and their role in main-
tenance of pluripotency.
Synthesis of micro-RNAs and their mode of action
MiRNAs were first described in the control of timing
during larval development of C. elegans [116]. Lee et al.
reported that lin-4, a gene essential for normal postem-
bryonic development, does not encode for a protein but was
complementary to the 30 untranslated region (UTR) of the
lin-14 transcript. Moreover, it has been shown that the
protein level of lin-14 negatively correlates with lin-4
expression, while the mRNA amount of lin-14 is unchan-
ged, indicative of a new level of control for transcriptional
homeostasis. Further studies revealed that lin-4 belongs to
a highly conserved class of ncRNAs, referred to as mi-
croRNAs (miRNAs), which act as an additional regulator
of gene expression.
In general, the synthesis of miRNAs begins in the
nucleus, where primary miRNAs (pri-miRNAs) are tran-
scribed by RNA-Polymerase II and III (for review, see
[117, 112]). The pri-miRNAs contain hairpin structures and
are processed by the nuclear microprocessor complex that
consists of the RNase III enzyme Drosha and the RNA
binding protein dgcr8. The resulting pre-miRNAs that still
show the characteristic stem-loops are exported to the
cytoplasm where they join with the RNAi pathway. Dicer,
another RNase III enzyme, recognizes the pre-miRNAs,
cuts off their loop and opts for one strand. The resulting
approximately 21 nucleotides are loaded into the RNA-
induced silencing complex (RISC), consisting of Dicer,
argonaute (Ago) class proteins and target mRNAs bearing
partially complementary sites in their 30-UTRs. The RISC
complex subsequently binds to its target mRNAs that are
silenced either through direct cleavage or translational
repression. For most miRNAs, the nucleotides 2–7 of their
sequence are decisive for target recognition. This region,
also referred to as ‘seed sequence’, binds to the target-
mRNA, unlike the whole miRNA sequence, in a perfect
complementary manner consequently exhibiting high
homology among related miRNAs. The detailed
3410 M. Bosnali et al.
mechanism of miRNA-mediated gene regulation is a mat-
ter of controversy. Substantially, there are two models that
also appear to complement one another. The first model
relies on the structural relationship of Ago-2 and the
translation initiation factor eIF4E. Since Ago-2 is recruited
by miRNAs, it has been proposed that silencing takes place
during translational initiation by inhibiting the recognition
of the cap structure of mRNAs by the translational appa-
ratus [118]. The second model suggests inhibition
subsequent to initiation, either by premature ribosome
drop-off and/or degradation of the nascent proteins [119,
120]. Finally, the mRNA is sequestrated in the cellular P
bodies either as an indirect result of translational inhibition
or directly resulting from miRNA targeting [121]. miRNA
genes are located throughout the genome in independent
transcription units, polycistronic clusters, or within the
intron regions of protein-coding genes [112]. Due to their
imperfect binding pattern, miRNAs usually target multiple
mRNAs. This, in combination with their expression pat-
tern, provides a versatile mechanism for the regulation of
developmental processes (Fig. 4).
Notably, down-regulation might not be the only way
how miRNAs regulate gene expression. Place et al.
recently described a direct activation of expression by
complementary binding of miRNA-373 to its targets’
promoter regions (E-cadherin and cold-shock domain-
containing protein C2) [122]. So far, little is known about
the RNAa-side of miRNAs but it gives a hint of hidden
layers of complexity that remain to be investigated.
Non-coding RNAs and their role in pluripotency
maintenance and self renewal
An indication for the involvement of miRNAs in pluripo-
tency control of ES cells has become obvious as miRNA
targets were found in the amino acid coding sequence of
Nanog, Oct4 and Sox2 [123]. Indeed, miRNAs such as
miR-134, miR-296 and miR-470 were found to be up-
regulated upon differentiation, leading to transcriptional
and morphological changes. Initial functional studies
addressing the role of nc-RNAs in stem cells were based on
genome-wide deletion of ncRNA-processing enzymes. It
was shown that Dicer-Null mouse embryos die around day
7.5 with an almost complete depletion of stem cells, which
is consistent with the finding of a premature down-regu-
lation of Oct4 [124]. Furthermore, Dicer-deficient ES cells
show a reduced rate of proliferation and severe defects in
differentiation [125–127]. Moreover, Dicer-null ES cells
also exhibit deficiencies in heterochromatin stability, telo-
mere homeostasis and silencing of transposons [125, 128],
which suggests a connection to epigenetic regulation.
Taken together, these findings indicate a multifaceted role
of ncRNAs during development and homeostasis with
complex, context-dependent functionalities. As a conse-
quence, ncRNA activities comprise a contribution to both
differentiation and self renewal of ES cells.
miRNAs are involved in cell cycle control
So far, 547 micro RNA genes have been identified in the
mouse genome and about half seem to be expressed in ES
cells (http://microrna.sanger.ac.uk)[129]. The phenotypes
of Dicer- and Drosha-deficient ES cells indicate that
miRNAs might be involved in cell cycle control. Murine ES
cells show high rates of proliferation, and generation times
of about 10 h [130]. The G1 phase is relatively short (*2 h)
for the benefit of a high percentage of cells in the S phase. In
differentiating cells, the situation is reversed, the fraction of
cells in S phase is lower, and the G1 phase elongated.
Recently, Wang et al. reported that ES cells deficient for
dgcr8, a RNA-binding protein essential for pri-miRNA
processing, show a prolonged G1 phase and defects during
differentiation [126]. In order to identify particular miRNAs
that are involved in cell cycle control, the authors screened a
miRNA library for the rescue of the proliferation defect. The
authors identified 14 miRNAs, most of which where in the
miR-290, miR-302 and miR-17-95 clusters. This finding is
in line with other studies reporting these clusters to be the
most abundant in ES cells. One of the miRNA candidate
targets, cdkn1a (cyclin-dependent kinase inhibitor 1a, also
designated as p21), is a gene of particular interest. Cdkn1a
inhibits the cyclin-dependent kinase 2 (cdk2) that is con-
stantly expressed during all stages of the ES cell cycle. ES
cells are unique in the continuous activity of cyclin:Cdk2
complexes throughout the cell cycle. Cdkn1a inhibits the
kinase activity of cyclin:Cdk2 complexes. Thus, the regu-
lation of cdkn1a expression level by miRNAs of the miR-
290, miR-302 and miR-17-95 clusters has a direct influence
on cdk2 activity. In fact, cdk2 decreases upon differentiation
of ES cells and consequently its cell cycle-dependent regu-
lation correlates with differentiation. The implication that
miRNAs of the miR-290 cluster positively regulate cdk2 in
an indirect manner was supported by miRNA overexpres-
sion studies. Coherently, transfection of ES cell with cdkn1a
show a similar G1-S delay as observed in Dgcr8 knockouts.
Intriguingly, analysis of the seed sequences demonstrated
that the identified miRNAs showed a high percentage of
redundancy suggesting highly regulated interactions. The
introduction of the 14 miRNAs in dgcr8-/- ES cells cells
rescued only the ES cell progression delay, the defects in
differentiation, however, remained unchanged [126].
Recently published studies confirmed the concept of func-
tional involvement of miRNAs in cell cycle control of stem
cells as miR-302b has been reported to directly influence
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Fig. 4 Simplified model of stemness control providing a holistic
view that combines the transcriptional network (left) with the
activities of non-coding RNAs (right). a Maintenance of stemness.
Transcription factors and miRNAs associated with pluripotency
balance each other to inhibit differentiation (box at the top in red) and
expedite proliferation (box at the bottom in green). b Differentiation.
After initiation of differentiation the transcriptional network and
miRNA expression change. Tissue-specific transcription factors and
miRNAs control accurate differentiation (top; here exemplified by
neural differentiation) resulting in a decrease in proliferation and
finally exit from the cell cycle (bottom). Activities of ncRNAs exert a
weighting and fine-tuning function, e.g., by removing residual
counteracting Oct4, Sox2 and Nanog transcripts from the system.
Various downstream effector molecules are exemplified. See text for
details
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cyclin D2 expression that shows increasing levels upon
differentiation [131].
miRNAs and their role in differentiation of stem cells
Certain miRNAs have been shown to regulate differen-
tiation and morphogenesis in a tissue-specific manner
[132–134]. For example, during neurogenesis, miRNAs
play an important role in the determination of neural
lineages from ESCs. Overexpression of miRNA-9 and
miRNA-124a in neural precursors lead to a reduction of
astrocyte differentiation, whereas knocking-down miR-9
results in a decrease of neurons [135]. Activation of the
Stat3 signaling pathway has been shown to inhibit terminal
neuronal differentiation [136, 137]. Indeed analysis of
Fig. 4 continued
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Stat3 revealed a negative correlation between the level of
its own phosphorylation and miRNA-9 and miRNA-124a
expression levels. These findings demonstrate how both
miRNAs could indirectly regulate neurogenesis (Fig. 4b).
Moreover, target analysis for miRNA-124 identified the
small C-terminal domain phosphatase 1 (SCP1) to be
posttranscriptionally regulated by miRNA-124. In turn,
timely down-regulation of SCP1 seems to be important for
induction of neurogenesis in mouse embryos [138].
In addition to tissue-specific miRNAs, there seem to be
classes of miRNAs that have a more general role in regu-
lating differentiation and depend rather on the
differentiation state than on a specific tissue. Tay et al.
[123] recently demonstrated that miRNAs genes are
involved in early stages of differentiation. The authors
report that upon retinoic acid-induced differentiation,
miRNA-134, miRNA-296 and miRNA-470 are up-regu-
lated. These miRNAs directly target the pluripotency
factors Oct4, Sox2 and Nanog. This observation indicates a
fine-tuning mechanism enabling the complete and rapid
disappearance of residual stem cell-specific mRNAs still
persisting after transcriptional down-regulation. Notably,
the miRNAs 134, 296 and 470 appear to target the mRNA
within the coding sequence, contrary to the classic view
that binding occurs only in the UTR. However, the specific
role of the miRNAs during differentiation remains to be
shown. Taking into consideration that miRNAs target a
high number of different transcripts, it will be of particular
interest whether the identified miRNAs act more generally
in weakening the pluripotency network and/or whether
they are actively incorporated in certain differentiation
pathways.
Another candidate with implications for a more gen-
eral role in differentiation processes is the let-7 family.
Comprising 12 members (let-7a1, a2, a3, b, c, d, e, f1,
f2, g, I, and miRNA-98), it is located on 8 different
chromosomes [139] and highly conserved among various
species [140]. In ES cells, let-7 expression is tightly
regulated, among others by lin28. Lin-28 binds to con-
served nucleotides within the loop region of the Let-7
precursor and inhibits the processing by Drosha [141]. In
mammalian development, let-7 is expressed late and
targets a broad set of cell cycle regulators such as
cdc25A and cdk6 [142], growth promoting pathways
including ras and c-Myc [143, 144] and early embryonic
genes such as hmga2, Mlin-41 and IMP-1 [145–148].
This mechanism provides a plausible explanation for the
observation that lin-28 is able to promote the induction
of pluripotency in somatic cells [98]. When co-expressed
together with Oct4, Sox2 and Nanog, lin-28 might mimic
the specific activities of Klf4 and c-Myc that represent
classical components of the ‘Yamanaka cocktail’ (Oct4,
Sox2, Klf4, and c-Myc).
Recently, 12 let-7 regulated oncofetal genes (LOGs)
were identified. These are suppressed by let-7 in most adult
tissues [147] and expressed in ES cells and various cancers.
Among them is the HMG AT-hook 2 (hmga2) gene,
encoding a stem cell factor that appears to modulate
maintenance of self-renewal of neural stem cells (NSCs) in
an age-dependent manner. Investigations employing
hmga2 knock-out mice revealed that although this factor is
not required for the generation of NSCs, its loss results in
defects in proliferation and self-renewal of this cell type.
Analyses of cdkn2a (p16INK4a/Arf) expression in NCSs
lacking Hmga2 showed a significant overexpression of
both tumor suppressor genes [149]. Normally, the cdkn2a
locus is activated late in fetal development and a guardian
against early neoplastic events such as uncontrolled
proliferation.
In conclusion, these observations allude to a model of
age-conditioned safeguard in which highly proliferative ES
cells and tissue-specific stem cells such as NSCs may self-
renew without being addressed as malignant. Aging cells in
contrast, where high proliferation may indicate aberrant
growth, are tightly controlled. For this, Hmga2 appears to
be a key regulator by inhibiting JunB and other targets that
presumably activate cdkn2a expression. Intriguingly,
Hmga2 is a direct target of Let-7 [147, 149]. Consequently,
mi-RNAs such as Let-7 have been hypothesized to be
guardians against pluripotency and inappropriate ways
toward stemness [150].
How transcriptional networks and non-coding RNAs
talk to each other
Cyclin D2 that is a direct target of miR-302 has been
shown to negatively correlate with the expression of Oct4
and Nanog. This indicates for an indirect regulation of
pluripotency-associated transcription factors by micro-
RNAs [131]. The analysis of a human embryonic carci-
noma line, whose miR-302 expression pattern strongly
resembles that of human ES cells, revealed high correla-
tion of miR-302b and Oct4 expression. Moreover, upon
retinoic acid-induced differentiation, the overexpression of
miR-302b could rescue Oct4 levels. Further indication of
miR-302’s role in the regulation of pluripotency derives
from overexpression experiments of the miR-302 cluster
in human skin cancer. The resulting cells show an altered
cellular phenotype resembling pluripotent human ES cells
[151]. It remains to be investigated whether this is due to
the balancing of the aberrant transcription network
towards pluripotency or whether miR-302s might directly
induce pluripotency.
Until recently, there were few data on the molecular and
functional interaction between the transcription factor
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machinery and the non-coding RNA circuitry controlling
stemness. Marson et al. reported high-resolution chromatin
immunoprecipitation data [152]. The authors identified
high-confidence miRNA promoters, based on chromatin
modifications and proximity to annotated miRNA-genes,
and linked them to binding maps of the transcription fac-
tors Oct4, Sox2, Nanog and Tcf3. By this, 55 miRNA
genes were identified whose promoters show binding sites
for all four factors. Thus, Oct4/Sox2/Nanog together with
Tcf3 regulate roughly 20% of miRNA and protein coding
genes. Interestingly, a quarter of these miRNAs has been
shown to be not actively transcribed in ES cells. Com-
prehensive epigenetic analysis of the promoters of these
miRNA genes showed a tri-methlyation mark at lysine 27
of histone 3 (H3K27me3) and enrichment for polycomb
proteins, both of which are characteristic for epigenetically
repressed genes. Consequently, it could be demonstrated
that these genes were up-regulated in differentiated cells as
compared to ES cells.
Other groups have also recently reported indications for
an epigenetic connection between miRNAs and pluripo-
tency factors. Benetti et al. and Sinkkonen et al. described
methylation defects in Dicer-deficient ES cells, concomi-
tant with increased telomere recombination and elongation
[128] and insufficient silencing of the Oct4 promoter dur-
ing differentiation [153]. Again, the miR-290 cluster turned
out to be of particular importance as it was identified as
targeting the retinoblastoma-like 2 protein (Rbl2), a tran-
scriptional repressor. Corresponding to high Rbl2 levels in
Dicer-null ES cells, the expression of DNA-methyltrans-
ferases (Dnmt), particularly the de-novo Dnmts 3a and 3b,
declined. The methylation defects could be rescued either
by expression of Dnmts or by transfection of miR-290s
[153], suggesting that miR-290 indirectly regulates epige-
netic modification through a transcriptional repressor.
Interestingly, the epigenetic defects only concerned DNA-
methylation whereas repressive histone modification
remained stable.
Concluding remarks and outlook
As we have described, studies in the last decade have
enabled researchers to get a comprehensive understanding
of how stemness maintenance in pluripotent cells is regu-
lated. In conclusion, the control of stemness properties in
ES cells appears complex (Fig. 4). ES cells show highly
accessible chromatin that makes them prone to transcrip-
tional leakiness and consequently holds risk for chaotic or
even dangerous resonance effects that might result in
apoptosis or malignances. This explains the need for buf-
fering the stemness machinery at different levels through
transcription factors, miRNAs, and epigenetic marks. This
is particularly important for genes whose inappropriate
expression results in undirected differentiation or malig-
nant proliferation. The groundbreaking work by Takahashi
and Yamanaka [6] demonstrated that a rather marginal
manipulation of the stemness network is sufficient to
induce pluripotency in somatic cells. Although the under-
lying mechanism remains elusive, researchers are
beginning to understand how transcriptional and miRNA
networks are talking to each other in order to decide a stem
cell’s fate. Initially, four virally transfected factors, Oct4,
Sox2, Klf4, and c-Myc, were reported to be sufficient to
induce pluripotency in fibroblasts [6]. A further study
reported that reprogramming of human ES cells is feasible
by another combination of factors, namely Oct4, Sox2,
Nanog, and LIN28 [98]. Taking these findings together,
Oct4 and Sox2 emerge as the two key regulators and
inducers of pluripotency. Nanog appears to play a role only
in promoting the induction of pluripotency, whereas the
miRNA-specific activities of LIN28 might mimic the
overexpression of Klf4 and c-Myc.
The derivation of iPS cells is a rather inefficient process
typically enabling only 1 in 1,000 recipient cells to be
reprogrammed. Several explanations may account for this
low efficiency. Due to the viral mode of factor delivery,
other factors might be involved in reprogramming that are
activated through random insertion of the transgenic viral
genome. Recent work, however, demonstrated that stable
viral integration is not required to generate iPS cells when
non-integrating adenoviruses or plasmids are used [154–
156]. Additionally, deletable viral constructs and non-viral
transponsons have been shown to induce pluripotency in
mouse and human ES cells [156, 157]. Thus, insertional
mutagenesis fails to explain the overall low efficiency of
transcription factor-induced reprogramming. One possible
explanation is that iPS generation requires rare stochastic
events. In contrast to well-balanced ES cells, some somatic
cell types might be more accessible to respond to tran-
scriptional noise at least in the artificial context of cell
culture. Rare cells might escape the transcriptional balance
determining the cellular phenotype, and then a comparably
weak trigger like Oct4-overexpression might be able to
induce a dramatic transcriptional switch. The imbalance
might be caused by factors like c-Myc, chemicals inter-
fering with key signaling pathways, or any cell culture
condition that increases transcriptional noise.
Stem cells exhibit very special cellular properties by
combining the ability to renew themselves and to differen-
tiate into specialized cell types. Thus, stem cells can be used
for cell replacement therapies and for studying differentia-
tion processes in vitro. Although ES cells as well as iPS cells
represent a virtually unlimited source of highly versatile
cells, clinical application is still in its infancy. Besides tar-
geted differentiation into the wanted cellular phenotype, the
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major limitation lies in gaining sufficiently tight control over
self-renewal activity after transplantation. Adult or somatic
stem cells by contrast that can be derived from multiple
organs of the adult organism, such as bone marrow, skin and
brain, have already been successfully applied in the clinics.
In fact, from a therapeutic point of view, pluripotency is not
a desirable criterion for cell replacement strategies. A reli-
able strategy to induce a multipotent or even unipotent state
might even be sufficient and much safer for clinical appli-
cations. Future studies will show whether or not researchers
will be able to gain sufficient insight into the stem cell
machinery and learn to precisely manipulate it in order to
determine any given cell type in the plastic dish.
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